WAY-649123 is an active molecule that exhibits (in vitro) antagonistic properties against (alpha-1A adrenergic receptors), with a (pKi) of 8.9. It also demonstrates a 70-fold selectivity over (alpha-1B) and 100-fold selectivity over (alpha-1D) subtypes. This compound has been shown to cross the blood-brain barrier (BBB) effectively in preclinical trials. Furthermore, WAY-649123 exhibits a high level of oral bioavailability and a favorable pharmacokinetic profile, making it a potential candidate for clinical development targeting conditions associated with (alpha-1A) receptors.